TGF-beta 1 Uses Distinct Mechanisms to Inhibit IFN-gamma Expression in CD4+ T Cells at Priming and at Recall: Differential Involvement of Stat4 and T-bet
Overview
Affiliations
TGF-beta1 plays a critical role in restraining pathogenic Th1 autoimmune responses in vivo, but the mechanisms that mediate TGF-beta1's suppressive effects on CD4(+) T cell expression of IFN-gamma expression remain incompletely understood. To evaluate mechanisms by which TGF-beta1 inhibits IFN-gamma expression in CD4(+) T cells, we primed naive wild-type murine BALB/c CD4(+) T cells in vitro under Th1 development conditions in the presence or the absence of added TGF-beta1. We found that the presence of TGF-beta1 during priming of CD4(+) T cells suppressed both IFN-gamma expression during priming as well as the development of Th1 effector cells expressing IFN-gamma at a recall stimulation. TGF-beta1 inhibited the development of IFN-gamma-expressing cells in a dose-dependent fashion and in the absence of APC, indicating that TGF-beta1 can inhibit Th1 development by acting directly on the CD4(+) T cell. During priming, TGF-beta1 strongly inhibited the expression of both T-bet (T box expressed in T cells) and Stat4. We evaluated the importance of these two molecules in the suppression of IFN-gamma expression at the two phases of Th1 responses. Enforced expression of T-bet by retrovirus prevented TGF-beta1's inhibition of Th1 development, but did not prevent TGF-beta1's inhibition of IFN-gamma expression at priming. Conversely, enforced expression of Stat4 partly prevented TGF-beta1's inhibition of IFN-gamma expression during priming, but did not prevent TGF-beta1's inhibition of Th1 development. These data show that TGF-beta1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4(+) T cells at priming and at recall.
Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy.
Lucas S, Thomas S Mol Pharm. 2024; 21(12):5929-5943.
PMID: 39478434 PMC: 11615947. DOI: 10.1021/acs.molpharmaceut.4c00692.
Defining Human Regulatory T Cells beyond FOXP3: The Need to Combine Phenotype with Function.
Gootjes C, Zwaginga J, Roep B, Nikolic T Cells. 2024; 13(11.
PMID: 38891073 PMC: 11172350. DOI: 10.3390/cells13110941.
Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer.
He Z, Zhang C, Zhao Y, He S, Li Y, Shi B Discov Oncol. 2023; 14(1):185.
PMID: 37857728 PMC: 10587041. DOI: 10.1007/s12672-023-00793-1.
Singh S, Gouri V, Samant M Med Oncol. 2023; 40(11):335.
PMID: 37855975 DOI: 10.1007/s12032-023-02204-5.
Jill N, Bhootra S, Kannanthodi S, Shanmugam G, Rakshit S, Rajak R Clin Exp Med. 2023; 23(8):4323-4339.
PMID: 37775649 DOI: 10.1007/s10238-023-01198-8.